Biophytis (EPA:ALBPS) | WebDisclosure

Basculer en Français

11290	Companies
250870	Keywords
179700	Articles
136709	Press releases

Home
Companies
Biophytis

REGULATED PRESS RELEASE

published on 09/11/2026 at 07:00, 1 month 25 days ago

BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Biophytis annonce une augmentation de capital de 5,3 millions d'euros pour financer l'essai de phase 2 dans l'obésité. L'opération est équilibrée entre investisseurs américains et européens

Biophytis Augmentation De Capital Investisseurs Essai Clinique Obésité
REGULATED PRESS RELEASE

published on 09/11/2026 at 07:00, 1 month 25 days ago

BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Biophytis completes €5.3 million capital increase to fund Phase 2 trial in obesity, balancing US and European investors. Proceeds target fat loss and muscle preservation with BIO101

Biophytis Capital Increase Phase 2 Trial BIO101 Obesity
BRIEF

published on 08/31/2026 at 07:05, 2 months 6 days ago

Biophytis Strengthens Financial Position with Cash Runway into 2027

Biophytis Debt Reduction Financial Restructuring Clinical Studies Share Warrants
BRIEF

published on 08/31/2026 at 07:05, 2 months 6 days ago

Biophytis renforce sa trésorerie et planifie de nouvelles études cliniques

Biophytis Actions En Circulation Études Cliniques Trésorerie Renforcée Diminution De La Dette
REGULATED PRESS RELEASE

published on 08/31/2026 at 07:00, 2 months 6 days ago

Biophytis renforce sa situation financière et étend son horizon de trésorerie au T1 2027
Biophytis renforce sa situation financière et étend son horizon de trésorerie au T1 2027. Position de trésorerie renforcée à 3,0 millions d'euros. Démarrage de l'étude de phase II dans l'obésité et joint-venture à Hong Kong sur le point de démarrer ses activités

Biophytis Hong Kong Trésorerie Obésité Phase II
REGULATED PRESS RELEASE

published on 08/31/2026 at 07:00, 2 months 6 days ago

Biophytis strengthens its financial position and extends its cash runway into Q1 2027
Biophytis strengthens financial position, extends cash runway to Q1 2027. Cash inflows of €3.7M, debt reduction of over 30%. Phase 2 study in obesity in Q1 2027

Biophytis Financial Position Debt Reduction Obesity Study Cash Runway
PRESS RELEASE

published on 08/31/2026 at 06:59, 2 months 6 days ago

Biophytis renforce sa situation financière et étend son horizon de trésorerie au T1 2027
Biophytis renforce sa situation financière en étendant son horizon de trésorerie au T1 2027 grâce à l'exercice des bons de souscription d'actions 2026 et à la réduction de sa dette. Démarrage imminent d'une étude de phase II dans l'obésité

Biophytis Restructuration Financière Trésorerie Étude Clinique Obésité
PRESS RELEASE

published on 08/31/2026 at 06:59, 2 months 6 days ago

Biophytis strengthens its financial position and extends its cash runway into Q1 2027
Biophytis strengthens financial position and extends cash runway to Q1 2027 through new resources and debt reduction, starting Phase 2 obesity study in Q1 2027

Biophytis Financial Position Debt Reduction Phase 2 Study Cash Runway
BRIEF

published on 08/10/2026 at 07:05, 2 months 27 days ago

Biophytis Secures Approval for OBA Clinical Trial in Brazil

Biophytis Obesity Treatment BIO101 GLP-1 Therapies OBA Clinical Trial
BRIEF

published on 08/10/2026 at 07:05, 2 months 27 days ago

Biophytis lance l'étude clinique OBA au Brésil avec BIO101

Biophytis Brésil BIO101 Obésité OBA Étude

Accesswire

Published on 11/06/2026 at 05:15, 4 hours 3 minutes ago

Valeo and QNX Unveil A New Smart Camera Platform at CIIE, Secures Multiple Design Wins
Published on 11/06/2026 at 01:20, 7 hours 58 minutes ago

Presentation to Munich Mining Conference
Published on 11/06/2026 at 00:53, 8 hours 25 minutes ago

Sekur Private Data Engages Darkstar Capital for Investor Awareness and Sekur Product Distribution
Published on 11/06/2026 at 00:45, 8 hours 33 minutes ago

Gabriel Announces Closure of ICSID Annulment Proceedings
Published on 11/05/2026 at 23:55, 9 hours 23 minutes ago

Santé Canada autorise deux vaccins à ARNm de Moderna : un vaccin contre la grippe et un vaccin combiné contre la grippe et la COVID-19

View all ACCESSWIRE

EQS Group

Published on 11/06/2026 at 09:04, 13 minutes ago

PARMANTIER & CIE. appoints Stefan Heieck and Harry Tyser as Senior Advisors
Published on 11/06/2026 at 09:01, 17 minutes ago

Original-Research: Nynomic AG (von NuWays AG): BUY
Published on 11/06/2026 at 09:00, 18 minutes ago

Nexum Group Listing – Trading on the Frankfurt Stock Exchange's Regulated Market has begun
Published on 11/06/2026 at 09:00, 18 minutes ago

Original-Research: DEMIRE AG (von NuWays AG): BUY
Published on 11/06/2026 at 09:00, 18 minutes ago

Original-Research: Deutsche Beteiligungs AG (von NuWays AG): BUY

Les Echos

Published on 11/06/2026 at 09:07, 11 minutes ago

Mise à disposition de la note d'information de M14 dans le cadre de l'OPR visant les actions BOURRELIER GROUP
Published on 11/06/2026 at 09:04, 13 minutes ago

Mise à disposition de la note d'information en réponse établie par BOURRELIER GROUP initiée par M14
Published on 11/05/2026 at 18:21, 14 hours 56 minutes ago

Capital et droits de vote au 31 octobre 2026
Published on 11/05/2026 at 18:21, 14 hours 56 minutes ago

Total number of voting rights and shares making up the share capital at October 31, 2026
Published on 11/05/2026 at 18:01, 15 hours 16 minutes ago

LNA SANTE : Chiffre d'Affaires T3 2026

View all LES ECHOS COMFI WIRE